Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.42 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 3/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | BAD | Q92934 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15233233 | 0.92 | — | — | |
| SCHEMBL5110 | 0.92 | — | — | |
| SCHEMBL22165011 | 0.89 | IDO1 (0.50) | MAOBIDO1LOXL2TRPA1ALDH1A1 | |
| SCHEMBL512431 | 0.89 | IDO1 (0.50) | MAOBIDO1LOXL2TRPA1ALDH1A1 | |
| SCHEMBL1835628 | 0.89 | IDO1 (0.50) | MAOBIDO1LOXL2TRPA1ALDH1A1 | |
| SCHEMBL9609757 | 0.86 | TSHR (0.56) | MAOBIDO1TRPA1ALDH1A1TSHR | |
| SCHEMBL679626 | 0.86 | TSHR (0.56) | MAOBIDO1TRPA1ALDH1A1TSHR | |
| SCHEMBL19300708 | 0.83 | AGXT (0.43) | MAOBIDO1LOXL2TAAR1PYCR1 | |
| Water SCHEMBL11481683 | 0.83 | TSHR (0.53) | MAOBIDO1TRPA1ALDH1A1TSHR | |
| Methane SCHEMBL11480910 | 0.83 | TSHR (0.53) | MAOBIDO1TRPA1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179017-A1 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| CN-119487006-A | Amide compounds as PGE2 receptor antagonists | 广东新契生物医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4482824-A1 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | Guangdong Newopp Biopharmaceuticals Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023160569-A9 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2024-03-07 | — | — | WO | disclosed |
| WO-2023160569-A1 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-08-31 | — | — | WO | disclosed |
| EP-3489237-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3489237-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | UNIV RUTGERS (US) | 2019-01-31 | — | — | US | disclosed |
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | UNIV RUTGERS (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180208593-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| WO-2015049574-A1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-09 | — | — | WO | disclosed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-0670322-B1 | A silacyclohexane compound, a method of preparing it and a liquid crystal composition containing it | SHINETSU CHEMICAL CO (JP) | 2000-01-19 | — | — | EP | disclosed |
| EP-0526402-B1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA GEIGY AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| EP-0670322-A1 | A silacyclohexane compound, a method of preparing it and a liquid crystal composition containing it | Shin-Etsu Chemical Co., Ltd. (JP) | 1995-09-06 | — | — | EP | disclosed |
| US-5350761-A | Lipoxygenase inhibitors as antiinflammatory agents and antiallergens | CIBA-GEIGY CORPORATION (US) | 1994-09-27 | — | — | US | disclosed |
| US-5334600-A | Lipoxygenase inhibitors | CIBA-GEIGY CORPORATION (US) | 1994-08-02 | — | — | US | disclosed |
| US-5260316-A | Lipoxygenase inhibitor | CIBA-GEIGY CORPORATION (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0526402-A1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA-GEIGY AG (CH) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | MAOB 3108/4885IDO1 3165/4885LOXL2 3406/4885 |
| US-20250179017-A1 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | PTGER1, PTGER2, CNR2 | MAOB 1948/4885IDO1 1495/4885LOXL2 1348/4885 |
| US-20180208593-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | MAOB 85/4885IDO1 255/4885LOXL2 2224/4885 |
| US-20150094328-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | MAOB 85/4885IDO1 255/4885LOXL2 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.